A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects

PHASE2CompletedINTERVENTIONAL

Enrollment

212

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

June 30, 2007

Study Completion Date

November 30, 2007

Conditions

Osteoporosis

Interventions

DRUG

100 mg AMG 162

100 mg AMG 162 (denosumab) SC every 6 months

DRUG

60 mg AMG 162

60 mg AMG 162 (denosumab) SC every 6 months

DRUG

14 mg AMG 162

14 mg AMG 162 (denosumab) SC every 6 months

DRUG

Placebo

Placebo SC every 6 months